Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

tags : Trial    save search

AFRM IMPORTANT DEADLINE MONDAY: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Affirm Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 6 Deadline in Securities Class Action - AFRM
Published: 2023-02-04 (Crawled : 00:20) - prnewswire.com
FXLV | News | $3.16 1.61% 0.0% 480K twitter stocktwits trandingview |
Arts, Entertainment, and Recrea...
| Email alert Add to watchlist
AFRM | News M | $18.14 -14.19% -16.54% 29M twitter stocktwits trandingview |
| Email alert Add to watchlist

trial deadline
FXLV IMPORTANT DEADLINE MONDAY: ROSEN, LEADING TRIAL ATTORNEYS, Encourages F45 Training Holdings Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 6 Deadline in Securities Class Action - FXLV
Published: 2023-02-04 (Crawled : 20:20) - prnewswire.com
FXLV | News | $3.16 1.61% 0.0% 480K twitter stocktwits trandingview |
Arts, Entertainment, and Recrea...
| Email alert Add to watchlist
BLRX | News | $0.62 1.39% 1.37% 320K twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

trial deadline
Sanofi Admits Defeat for Myasthenia Gravis Candidate, Drops Phase III Trial
Published: 2023-02-03 (Crawled : 16:00) - biospace.com/
SNY | News | $46.02 -2.58% -2.65% 3.5M twitter stocktwits trandingview |
Health Technology
| | O: -4.01% H: 0.0% C: 0.0%

for trial sanofi
Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting
Published: 2023-02-03 (Crawled : 14:20) - prnewswire.com
BPMC | $45.64 -6.97% -7.49% 810K twitter stocktwits trandingview |
Health Technology
| | O: 5.37% H: 0.0% C: 0.0%

ayvakit meeting trial positive
Patent Trial and Appeal Board (PTAB) Reaffirms Decision to Invalidate All Claims of United Therapeutics (UTHR) Patent No. 10,716,793 (‘793 Patent)
Published: 2023-02-02 (Crawled : 22:00) - globenewswire.com
UTHR M | $252.81 -2.57% -2.64% 500K twitter stocktwits trandingview |
Health Technology
| | O: 0.59% H: 0.0% C: 0.0%

patent trial therapeutics
Skye Bioscience Retains Lexitas Pharma Services as CRO for Phase 2 Trial of SBI-100 Ophthalmic Emulsion
Published: 2023-02-02 (Crawled : 16:00) - biospace.com/
SKYE | $0.0503 0 twitter stocktwits trandingview |
Transportation and Warehousing
| Email alert Add to watchlist

sbi-100 pharma services for trial bioscience
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight LossExpects to Commence Phase 2a of CAReS During the First Quarter of 2023
Published: 2023-02-02 (Crawled : 15:20) - biospace.com/
AZN | $63.45 0.48% 0.47% 4.8M twitter stocktwits trandingview |
Health Technology
| | O: -0.33% H: 0.0% C: 0.0%
ARTL A | $3.06 -0.65% -0.65% 36K twitter stocktwits trandingview |
Health Technology
| | O: -1.27% H: 0.0% C: 0.0%

art27 treatment cares for trial art27.13
Amylyx Pharmaceuticals Announces Completion of Enrollment in Global Phase 3 PHOENIX Trial of AMX0035 in ALS
Published: 2023-02-02 (Crawled : 15:00) - biospace.com/
AMLX | $36.6 -1.08% -1.09% 650K twitter stocktwits trandingview |
| | O: -0.2% H: 3.98% C: -5.88%

amx0035 pharmaceuticals global als trial
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Published: 2023-02-02 (Crawled : 14:20) - globenewswire.com
AZN | $63.45 0.48% 0.47% 4.8M twitter stocktwits trandingview |
Health Technology
| | O: -0.33% H: 0.0% C: 0.0%
ARTL A | $3.06 -0.65% -0.65% 36K twitter stocktwits trandingview |
Health Technology
| | O: -1.27% H: 0.0% C: 0.0%

art27 treatment cares for trial art27.13
Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
Published: 2023-02-02 (Crawled : 14:00) - biospace.com/
AVXL | $11.27 -0.88% -0.89% 1.1M twitter stocktwits trandingview |
Health Technology
| | O: 2.76% H: 0.0% C: 0.0%

anavex anavex®2-73 trial rett syndrome
MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa
Published: 2023-02-02 (Crawled : 13:20) - globenewswire.com
MLTX | $12.08 0.25% 0.25% 85K twitter stocktwits trandingview |
| | O: 2.51% H: 1.71% C: -1.63%
SNY | News | $46.02 -2.58% -2.65% 3.5M twitter stocktwits trandingview |
Health Technology
| | O: -1.44% H: 0.0% C: 0.0%

nanobody trial
First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic FibrosisPatient dosing expected to begin in mid-February with topline data anticipated by mid-2023
Published: 2023-02-02 (Crawled : 13:00) - biospace.com/
FWBI | $5.14 -5.34% -5.64% 270K twitter stocktwits trandingview |
Manufacturing
| | O: -3.21% H: 25.54% C: 5.85%

biopharma for topline expected trial
NRx Pharmaceuticals Reports Recommendations of Data Safety Monitoring Board for Trial of NRX-101 in Patients with Severe Bipolar Depression and Subacute Suicidal Ideation or Behavior
Published: 2023-02-02 (Crawled : 12:00) - prnewswire.com
NRXP | $1.255 0.4% 0.4% 130K twitter stocktwits trandingview |
Manufacturing
| | O: -0.85% H: 6.84% C: 6.84%

nrx-101 pharmaceuticals for trial depression
NBEV DEADLINE: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages NewAge Inc. Investors to Secure Counsel Before Important February 6 Deadline in Securities Class Action Initiated by the Firm - NBEV, NBEVQ
Published: 2023-02-02 (Crawled : 01:00) - prnewswire.com
TTCF | $1.65 -4.07% -4.24% 1.4M twitter stocktwits trandingview |
Consumer Non-Durables
| | O: 9.15% H: 10.18% C: 2.99%
SPPI S | $0.829 2.88% 2.8% 2M twitter stocktwits trandingview |
Health Technology
| | O: 28.17% H: 1.1% C: -11.45%

trial trusted deadline initiated
Mersana Therapeutics Initiates Expansion Portion of UPGRADE-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer
Published: 2023-02-01 (Crawled : 15:00) - biospace.com/
MRSN | $7.025 1.96% 1.92% 1.3M twitter stocktwits trandingview |
Health Technology
| | O: 0.15% H: 3.03% C: 1.97%

expansion trial therapeutics cancer
GreenLight Biosciences receives approval to initiate Phase I/II clinical trial of Covid-19 mRNA vaccine candidate
Published: 2023-02-01 (Crawled : 14:00) - biospace.com/
GRNA | $1.135 1.34% 1.32% 220K twitter stocktwits trandingview |
Professional, Scientific, and T...
| | O: 9.76% H: 0.0% C: -5.87%

covid-19 candidate vaccine mrna trial approval
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Tattooed Chef, Inc. Investors to Secure Counsel Before Important Deadline in First Filed Securities Class Action Commenced by the Firm - TTCF
Published: 2023-02-01 (Crawled : 04:00) - prnewswire.com
TTCF | $1.65 -4.07% -4.24% 1.4M twitter stocktwits trandingview |
Consumer Non-Durables
| | O: -1.29% H: 0.0% C: 0.0%
DAKT | $4.12 -0.48% -0.49% 260K twitter stocktwits trandingview |
Electronic Technology
| | O: 1.47% H: 2.77% C: 0.96%

trial deadline
AtriCure Announces the First Patient Treated in the LeAAPS™ Clinical Trial
Published: 2023-01-31 (Crawled : 17:00) - biospace.com/
ATRC | $47.23 0.02% 0.02% 190K twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

trial
Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis
Published: 2023-01-31 (Crawled : 14:00) - biospace.com/
ARCT | $21.97 -4.1% -4.28% 370K twitter stocktwits trandingview |
Health Technology
| | O: -0.64% H: 4.14% C: 4.14%

arct-032 fibrosis for application trial approval therapeutics
First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis
Published: 2023-01-31 (Crawled : 13:00) - biospace.com/
FWBI | $5.14 -5.34% -5.64% 270K twitter stocktwits trandingview |
Manufacturing
| | O: -0.9% H: 4.88% C: -1.99%

biopharma fibrosis trial pancreatic
Gainers vs Losers
63% 37%

Top 10 Gainers

Your saved searches
Save your searches and get alerts when important news are released.